Clinical characteristics of NPS positive, NPS negative/clinically positive and NPS negative/other clinical diagnoses
| Clinical characteristics | SARS-CoV-2 NPS positive (n=16) | SARS-CoV-2 NPS negative/clinically positive (n=15) | SARS-CoV-2 NPS negative/other diagnosis (n=9) |
| Median age (range) | 40.5 (31–69) | 68 (32–95) | 47 (27–73) |
| No. of male (%) | 12 (75) | 13 (86.6) | 3 (33) |
| Median BMI (range) | 28 (20.2–37.9) | 26.35 (23–28.4) | 26.8 (23–30) |
| Smokers (%) | 3 (18.7) | 6 (40) | 4 (44) |
| Lab results (range) | |||
| Ferritin ng/mL (30–400) | 1182 (224–2705) | 875 (316–21 063) | 336.5 (256–1979) |
| Lactate dehydrogenase IU/L (135–214) | 333 (276–794) | 262 (162–825) | 310.5 (190–322) |
| D-dimer ug/mL (0–0.5) | 1.03 (0.9–35) | 1.26 (0.42–15) | 3.33 (0.89–71.4) |
| Pa02 kPa (11.1–14.1) | 8.9 (7.5–11.5) | 8.9 (7.8–12) | 11.1 (7–16.5) |
| C reactive protein mg/L (0–5) | 166.5 (15–274) | 166 (37.3–293) | 47 (1–308) |
| Lymphocytes 109/L (1–4) | 0.81 (0.4–1.67) | 0.86 (0.26–1.11) | 1.63 (0.62–1.52) |
| Troponin ng/L (0–13) | <14 (14–58) | <14 (14–54) | <14 (14–75) |
| Median temperature (range) | 37.85 (35.9–41) | 37.1 (36.4–39) | 37 (36.1–37.8) |
| Median number of NPSs (range) | 1 (1) | 2 (2–3) | 1 (1–3) |
| Median no. of days symptomatic pre-NPSs (range) | 10 (4–20) | 7 (3–16) | 5 (2–10) |
| NPS/EBC interval – median (range) (days) | 3 (1–19) | 1 (0–7) | 1 (0–5) |
EBC, exhaled breath condensate; NPS, nasopharyngeal swab.